Needham Reiterates Buy on Praxis Precision Medicine, Maintains $145 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $145.
September 03, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine and maintained a price target of $145, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100